Study S002181

A Multicenter, Randomized, Open-label, Parallel-group, Active-controlled Clinical Trial to Evaluate Efficacy and Safety of QLG1091 Versus Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT07487103
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 478
Start: 2026-05-01
Primary completion: 2026-12
Lead sponsor: Qilu Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:QLG1091; DRUG:Rybelsus
Results posted: FALSE

Registered primary outcomes

Change in HbA1c [Week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.